Medivir AB: MIV-247 Has Been Selected as a Candidate Drug and Enters Development for the Treatment of Neuropathic Pain

Published: Oct 10, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

STOCKHOLM--(BUSINESS WIRE)--Medivir AB (OMX:MVIR) (STO:MVIR-B) announced that MIV-247 has been selected as a candidate drug (CD) from its cathepsin S inhibitor project for the treatment of neuropathic pain, and is entering non-clinical development. Approximately 25 million patients across the US, Europe and Japan suffer from neuropathic pain, which includes diabetic neuropathy, post-herpetic neuralgia and neuropathic low-back pain. Currently marketed drugs have limited efficacy and poor side-effect profiles. Patients with neuropathic pain are therefore in great need of new and efficacious therapies that can deliver sustainable pain relief with improved tolerance and adverse event profiles.

Help employers find you! Check out all the jobs and post your resume.

Back to news